Segal Cancer Centre

At first, telehealth seemed like a distant dream. But when COVID-19 hit, the CIUSSS and the JGH made telehealth a part of daily life.

The Segal Cancer Centre at the JGH has responded to COVID-19 with compassion and innovation by enabling patients can consult with oncologists by video as an alternative to face-to-face meetings.

Individuals with cancer need to be perceived primarily as people, and not as cases or a collection of symptoms. That’s the focus of a research paper whose JGH co-authors have been honoured with a Best Publication award by the Canadian Association of Nurses in Oncology.

Two LDI researchers have been elected to the Canadian Academy of Health Sciences. Dr. Carmen Loiselle is Co-Director (Academic) of the Segal Cancer Centre. Dr. Cécile Rousseau’s career is dedicated to understanding the effects of organized violence on children and families.

In 2006, Health and Social Services Minister Philippe Couillard visited the newly completed Segal Cancer Centre to express his admiration for the JGH’s leadership in providing patients with a fully integrated system of cancer treatment and care.

To enable advanced cancer patients to cope with difficulties at the end of life, JGH researchers hope to develop better psychological support through an intervention that helps individuals find meaning in their radically altered lives.

A pioneering research program is connecting artificial intelligence with the new field of radiomics to heighten the effectiveness of cancer treatment by gleaning as much information as possible from radiological imaging technology.

Ten years after its debut, the Enbridge Ride to Conquer Cancer reached its landmark anniversary on July 7 and 8, with 1,308 participants raising more than $4.8 million for the Segal Cancer Centre and its partners across Quebec.

After a demanding, 200-kilometre ride from Montreal to Quebec City, 1,100 cyclists in the 9th annual Enbridge Ride to Conquer Cancer raised $4.1 million for the JGH and its partners across Quebec.

A unique phase 2 clinical trial, led by researchers in the Segal Cancer Centre at the JGH, has resulted in a remission of diffuse large B-cell lymphoma for patients who have relapsed and have a particularly dire prognosis.